💊 The most powerful obesity drug yet just showed its numbers

Retatrutide — Eli Lilly's next step beyond Ozempic and Wegovy — just posted late-stage trial results. Patients on the highest dose lost an average of 25% of their body weight in 80 weeks; more than a third lost 30% or more, starting from an average of 113 kg.

The side effects were strictly good: knee pain down 62%, sleep apnea events down 57%, prediabetes resolved in over 90% of those who had it — all published today in the New England Journal of Medicine.

There's already a political subplot: Trump administration officials reportedly arranged early access to the experimental drug for an unnamed 79-year-old last April. The age and the timing do the rest of the work.

Ars Technica